KATHERINE BRANUM: Open Payments
NPI 1306034087 · TROY, AL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,445 in 88 payments from 19 companies in 2025. Trend: 2023 $1,573 · 2024 $1,371 · 2025 $1,445
Food & beverage: $1,445
| Company | Payments | Amount |
|---|---|---|
| Lilly USA, LLC | 18 | $253 |
| AstraZeneca Pharmaceuticals LP | 11 | $203 |
| Novo Nordisk Inc | 12 | $163 |
| Amgen Inc. | 12 | $145 |
| Bayer Healthcare Pharmaceuticals Inc. | 4 | $104 |
| Astellas Pharma US Inc | 5 | $99 |
| Phathom Pharmaceuticals, Inc. | 4 | $74 |
| Merck Sharp & Dohme LLC | 4 | $74 |
| GlaxoSmithKline, LLC. | 4 | $72 |
| Sumitomo Pharma America, Inc. | 3 | $49 |
Products named: MOUNJARO, Ozempic, EVENITY, JARDIANCE, Kerendia, Veozah, FARXIGA, VOQUEZNA.
Industry payments across AL — which companies pay providers there.
